Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis

Experimental Cell Research

Volumn 318, Issue 11, 2012, Pages 1208-1212

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; HDAC; TRAIL

Indexed keywords

APICIDIN; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CYCLOPEPTIDE; DEATH RECEPTOR; DEPSIPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LAQ 842; OXAMFLATIN; REGULATOR PROTEIN; TRAPOXIN A; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; CHROMATIN STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

EID: 84861683009     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.005     Document Type: Review

References (41)

1. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
2. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5:769-784.
3. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
4. Nightingale K.P., O'Neill L.P., Turner B.M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 2006, 16:125-136.
5. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005, 23:3971-3993.
6. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63:7291-7300.
7. Camphausen K., Scott T., Sproull M., Tofilon P.J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 2004, 10:6066-6071.
8. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8:132-140.
9. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
10. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discovery 2010, 9:447-464.
11. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004, 11(Suppl 2):S193-S206.
12. Kim Y.H., Park J.W., Lee J.Y., Kwon T.K. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004, 25:1813-1820.
13. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-6271.
14. Guo F., Sigua C., Tao J., Bali P., George P., Li Y., Wittmann S., Moscinski L., Atadja P., Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004, 64:2580-2589.
15. Singh T.R., Shankar S., Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24:4609-4623.
16. Chopin V., Slomianny C., Hondermarck H., Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell. Res. 2004, 298:560-573.
17. VanOosten R.L., Moore J.M., Karacay B., Griffith T.S. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol. Ther. 2005, 4:1104-1112.
18. Earel J.K., VanOosten R.L., Griffith T.S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006, 66:499-507.
19. Butler L.M., Liapis V., Bouralexis S., Welldon K., Hay S., Thai le M., Labrinidis A., Tilley W.D., Findlay D.M., Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int. J. Cancer 2006, 119:944-954.
20. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003, 2:1273-1284.
21. Vanoosten R.L., Moore J.M., Ludwig A.T., Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 2005, 11:542-552.
22. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., Debatin K.M., Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
23. Fulda S., Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002, 21:2295-2308.
24. Pathil A., Armeanu S., Venturelli S., Mascagni P., Weiss T.S., Gregor M., Lauer U.M., Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006, 43:425-434.
25. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., Shen T., Murphy T., Wickham J., Kanakry C., Lucas D.M., Reed J.C., Grever M.R., Byrd J.C. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003, 102:652-658.
26. Watanabe K., Okamoto K., Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 2005, 12:10-18.
27. Hernandez A., Thomas R., Smith F., Sandberg J., Kim S., Chung D.H., Evers B.M. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001, 130:265-272.
28. Schuchmann M., Schulze-Bergkamen H., Fleischer B., Schattenberg J.M., Siebler J., Weinmann A., Teufel A., Worns M., Fischer T., Strand S., Lohse A.W., Galle P.R. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol. Rep. 2006, 15:227-230.
29. Micheau O. Cellular FLICE-inhibitory protein: an update. Apoptosis and Cancer Therapy 2006, 120-157. Wiley-VCH, Heidelberg. K.M. Debatin, S. Fulda (Eds.).
30. Bangert A., Cristofanon S., Eckhardt I., Abhari B.A., Kolodziej S., Hacker S., Vellanki S.H., Lausen J., Debatin K.M., Fulda S. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene Jan. 23 2012, [Epub ahead of print].
31. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
32. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Disc 2012, 11:109-124.
33. Reddy R.M., Yeow W.S., Chua A., Nguyen D.M., Baras A., Ziauddin M.F., Shamimi-Noori S.M., Maxhimer J.B., Schrump D.S. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 2007, 12:55-71.
34. Ziauddin M.F., Yeow W.S., Maxhimer J.B., Baras A., Chua A., Reddy R.M., Tsai W., Cole G.W., Schrump D.S., Nguyen D.M. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 2006, 8:446-457.
35. El-Zawahry A., Lu P., White S.J., Voelkel-Johnson C. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther. 2006, 13:281-289.
36. Neuzil J., Swettenham E., Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem. Biophys. Res. Commun. 2004, 314:186-191.
37. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 2004, 3:425-435.
38. Gillespie S., Borrow J., Zhang X.D., Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006, 11:2251-2265.
39. Muhlethaler-Mottet A., Flahaut M., Bourloud K.B., Auderset K., Meier R., Joseph J.M., Gross N. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006, 6:214.
40. Spiegel S., Milstien S., Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012, 31:537-551.
41. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., Baer M.R., Holleran J.L., Egorin M.J., Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2009, 15:5250-5257.